今日药学

2020, v.30(03) 157-159+167

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

雾化吸入IFN-α治疗病毒性疾病的研究进展
Research Progress on Aerosol Inhalation of Α-interferon in Treating Viral Diseases

周花萍;吴红卫;
ZHOU Huaping;WU Hongwei;Guangzhou 8th People's Hospital;The First Affiliated Hospital of Guangdong Pharmaceutical University;

摘要(Abstract):

目的探索IFN-α(IFN-α)在非典(SARS)、中东呼吸综合征(MERS)和儿童病毒性疾病中的作用,为IFN-α治疗新型冠状病毒肺炎(COVID-19)的临床研究提供一些可借鉴的思路。方法通过检索国内外数据库,获取与IFN-α相关的数据。结果目前尚缺乏IFN-α治疗NCP临床研究数据,IFN-α对SRAS的疗效尚未肯定,对MERS的最佳治疗方法仍未达成共识。但在儿童病毒性疾病中,雾化吸入IFN-α具有作用迅速、疗效可靠、用药剂量小、全身不良反应少等优点,在我国儿童中广泛应用。结论目前尚无NCP的特效药,IFN-α对新冠肺炎的疗效和安全性需要更进一步的临床研究。
OBJECTIVE To explore the role of α-interferon(IFN-α) in severe acute respiratory syndrome(SARS) 、Middle East respiratory syndrome(MERS) and viral diseases of children,in order to provide some useful ideas for clinical study of IFN-α in novel coronavirus pneumonia(COVID-19). METHODS By searching databases at home and abroad,extracted data related with IFN-α.RESULTS Now there was few clinical research data about α-interferon in the treatment of NCP. Its effects on SARS had not been confirmed,and there was no consensus on the best treatment of MERS. Aerosol inhalation of IFN-α had the advantages of rapid action,reliable effect,small dosage,less systemic adverse reactions and so on in children 's viral diseases,and had been widely used.CONCLUSION At present,there were no specific therapeutic drugs.It need more clinical studies on the the efficacy and safety of α-interferon in NCP.

关键词(KeyWords): IFN-α;雾化吸入;新型冠状病毒肺炎;冠状病毒
α-interferon;atomization inhalation;COVID-19;coronavirus

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周花萍;吴红卫;
ZHOU Huaping;WU Hongwei;Guangzhou 8th People's Hospital;The First Affiliated Hospital of Guangdong Pharmaceutical University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享